Zacks Research Comments on STERIS’s Q2 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Zacks Research boosted their Q2 2027 earnings per share estimates for STERIS in a research report issued on Wednesday, November 27th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.58 for the quarter, up from their prior estimate of $2.51. The consensus estimate for STERIS’s current full-year earnings is $9.12 per share.

A number of other brokerages have also recently commented on STE. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Friday, November 8th. Stephens restated an “overweight” rating and issued a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. KeyCorp raised their target price on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Finally, Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and raised their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.00.

STERIS Trading Down 1.0 %

Shares of STERIS stock opened at $216.65 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. STERIS has a 52 week low of $195.50 and a 52 week high of $248.24. The stock has a 50 day moving average price of $224.16 and a two-hundred day moving average price of $228.04. The stock has a market capitalization of $21.39 billion, a PE ratio of 49.46 and a beta of 0.83.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter last year, the firm posted $2.03 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a yield of 1.05%. STERIS’s dividend payout ratio (DPR) is currently 52.05%.

Insider Buying and Selling

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. The trade was a 35.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Institutional Trading of STERIS

Several hedge funds have recently made changes to their positions in the company. West Coast Financial LLC raised its stake in shares of STERIS by 2.8% in the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider’s stock valued at $398,000 after buying an additional 45 shares during the period. Taylor Frigon Capital Management LLC grew its position in shares of STERIS by 0.8% in the second quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider’s stock valued at $1,356,000 after purchasing an additional 46 shares in the last quarter. SkyView Investment Advisors LLC grew its position in shares of STERIS by 1.6% in the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider’s stock valued at $765,000 after purchasing an additional 51 shares in the last quarter. Mather Group LLC. grew its position in shares of STERIS by 7.6% in the second quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider’s stock valued at $172,000 after purchasing an additional 54 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of STERIS by 16.5% in the first quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 57 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.